<SEC-DOCUMENT>0001104659-20-039253.txt : 20200327
<SEC-HEADER>0001104659-20-039253.hdr.sgml : 20200327
<ACCEPTANCE-DATETIME>20200327080145
ACCESSION NUMBER:		0001104659-20-039253
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20200327
DATE AS OF CHANGE:		20200327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-214882
		FILM NUMBER:		20748076

	BUSINESS ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827
		BUSINESS PHONE:		908-200-7500

	MAIL ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>a20-13830_1424b5.htm
<DESCRIPTION>424B5
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Filed Pursuant to Rule&nbsp;424(b)(5)</font></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registration No.&nbsp;333-214882</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">PROSPECTUS SUPPLEMENT</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(To Prospectus Supplement dated November&nbsp;9, 2017</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">and Prospectus dated February&nbsp;13, 2017)</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="137" height="43" src="g138301bai001.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CELLDEX THERAPEUTICS,&nbsp;INC.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Up to $18,000,000</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Common Stock</font></b></p>
<div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade align="center" style="color:black;"></div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This prospectus supplement amends and supplements the information in our prospectus, dated February&nbsp;13, 2017, supplemented on November&nbsp;9, 2017 (File No.&nbsp;333-214882) (the &#147;Prospectus&#148;). This prospectus supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This prospectus supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments or supplements thereto.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">In accordance with the terms of the Controlled Equity Offering</font><font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">SM</font>&#160;sales agreement (the &#147;Sales Agreement&#148;), dated May&nbsp;19, 2016, we entered into with Cantor Fitzgerald&nbsp;&amp; Co., or Cantor Fitzgerald, we may offer and sell shares of our common stock from time to time through Cantor Fitzgerald, acting as sales agent.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On March&nbsp;26, 2020, the date we filed our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019, our Prospectus became subject to the offering limits in General Instruction I.B.6 of Registration Statement on Form&nbsp;S-3.&#160; At that time, based on the highest closing sale price of our common stock on the Nasdaq Capital Market, or Nasdaq, within the prior 60 days and the number of shares of our outstanding common stock held by non-affiliates, we were eligible under General Instruction I.B.6 to offer and sell up to at least $18,000,000 of shares of our common stock.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">We are filing this prospectus supplement to amend the Prospectus to update the amount of shares we are eligible to sell under General Instruction I.B.6. As a result of these limitations and the current public float of our common stock, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $18,000,000 from time to time through Cantor Fitzgerald. If our public float increases such that we may sell additional amounts under the Sales Agreement and the registration statement and Prospectus of which this Prospectus Supplement and the Sales Agreement Prospectus are a part, we will file another prospectus supplement prior to making additional sales.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Our common stock is listed on the Nasdaq Capital Market, or Nasdaq, under the symbol &#147;CLDX&#148;. On March&nbsp;26, 2020, the last reported sales price of our common stock on Nasdaq was $1.79 per share. As of March&nbsp;26, 2020, the aggregate market value of our common stock held by non-affiliates, or the public float, pursuant to General Instruction I.B.6 of Form&nbsp;S-3 was $54,049,137, which was calculated based on 17,605,582 shares of our common stock outstanding held by non-affiliates as of March&nbsp;26, 2020 and at a price of $3.07 per share, the last reported sale price for our common stock on February&nbsp;21, 2020. As of the date hereof, we have not offered and sold any common stock pursuant to General Instruction I.B.6 of Form&nbsp;S-3 during the prior 12 calendar month period that ends on and includes the date hereof.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Investing in our common stock involves risks. Before buying any shares, you should read the discussion of material risks of investing in our common stock in &#147;Risk Factors&#148; beginning</font></b>  <b>on page&nbsp;4 of the Prospectus, and in the risks discussed under similar headings in the documents incorporated by reference in this prospectus supplement and the Prospectus, as they may be amended, updated or modified periodically in our reports filed with the Securities and Exchange Commission.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement and the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="234" height="49" src="g138301bai002.jpg"></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The date of this prospectus supplement is March&nbsp;27, 2020.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\105569\20-13830-1\task9655158\13830-1-ba.htm',USER='105569',CD='Mar 27 06:55 2020' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g138301bai001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g138301bai001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  K (D# 2(  A$! Q$!_\0
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**TJ6B@:BH['_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g138301bai002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g138301bai002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  Q .H# 2(  A$! Q$!_\0
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M^';.UMXGMVO5$TJ,PW!,_*#CUZ_2NAQK2M&6QAS4HIR1Q/B+6I?$&N7%],2
M[?(N?N*. *T=(\-FZ\'ZOJ\J9$(5("?7<-Q_I7-JH9@,@!L#)[>]>LR>(/"]
MMX%ET:UU.%F%N4 "M\SXSZ>M==5N"C&)S02FW*1Y,>>1TKW_ ,"WHN_!FGRL
MV2D6PGW7@U\_UZGX U<0?#_50S<VN\@>F1D?J:C%1YHIE8>7*V>=:Y=&]UR^
MN"<^9,Q_6J84E2V#@=3C@4A.XD]R<UWG@CPRNO>$]94C]XS 1'_:49%;2FJ<
M5<R47.3L<EH>JR:)K-M?1$CRG!8#NO<5TGQ.U2/4]=M6A8-$MLK#'^US7'2Q
MO#*\<@*NC%6![&D>1I,;V+8&!GL/2AP3FICYVHN)=T.U-YKEC;@9WS*,?C7T
MDB!$"J, # KPCX;VGVOQG:''$(:0_@*]XSQ7%C'>=CKPJ]VYYM\8KH+86%J,
M9DD+GCL!7D_:N\^+EYYWB6"WSD00C]37"QH9)D0=68 ?G75AURT[G/7=ZECW
MGP!:"Q\%6.>-ZF1L^YKQ_P 8ZP^M>);N<D^6CF.,9R J\5[B(OL'A@1 8,-K
MC ]EKYS)+$L>IYK#"KFFY,TQ#Y8J)TGP_P!-74_%]HDB@QQ$RL#WV]/UKWT#
MBO&/A( ?$\^<9^SG&?J*]FSBLL8VYFN%2Y#SCXQ6,1TVRO< 2I+Y>?52#_A7
MDV?P->E_&'54DFLM-1LLF9I .W8?UKS0 ],$GT]:[,-=4U<YJ]G/0Z#5KUF\
M&:':%LJ'FDV^P.!_,TGAKQGJ?AF4>1)YMJ3E[>0_*?<?W3[U7\11&TELK(_>
MM[1-X/9FRY'_ (\/RK*CC>65(XU+.Y"J!U)Z"JC"+B[D.34M#Z&\/^)K+Q%I
MOVJQ))3B6$XWHV.A'OV->6_$+QLOB+R]/M[6:WBMY2S^>-K[QD8V]L<]ZI:3
MHGB[P]>+?66F7:,@^90N0X]" >1_D8K5\7V5KXFT@>)])4I+'\E_ ?O1D<9(
M]1T^G/:N2$(4ZE]SIE.4X6V..TC2+K7-2BLK"(R2N>>.$7/+-Z 9KW^Q\/65
MEI]M:B!)!!$L>\J,M@ 9_2O+OAGXGFL=8@TB2.(VUR2H8( Z/@D<CDCJ.<]J
M]B\H'G _3_"EBJDU*R'AZ<7&[/,?B]H+F6WUF"/* >5<$#I_=)_4?E7F%?3M
MQ;1743Q3QK)&X*LK#((KSS6O@_:W$KRZ/=M:YY$,B[T'T/4#ZYJL/B%%<LQ5
MJ#;YHG)Z9\3M>TRP2T!M[A4 5'F0E@!VR"*Y_6-;OM>O3=:C.99,;5'15'H
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,B@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
